** Cancer testing services firm NeoGenomics' NEO.O shares fall 3.6% to $9.61 premarket
** Company reports Q1 revenue of $168 million, missing analysts' estimates of $171 million, according to data compiled by LSEG
** But company raises its annual revenue forecast to be between $747 million and $759 million, up from previous range of $735 million to $745 million
** Separately, company says it is collaborating with biotech firm Ultima Genomics to expand clinical test offerings for cancer patients using Ultima's sequencing platform designed for large-scale genomic studies
** As of last close, NEO has fallen 39.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.